NYSE - Delayed Quote USD

Teva Pharmaceutical Industries Limited (TEVA)

13.81 +0.56 (+4.23%)
At close: April 26 at 4:00 PM EDT
13.89 +0.08 (+0.58%)
After hours: April 26 at 6:54 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for TEVA

Recent News: TEVA

View More

UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
Reuters 4 days ago
11 Best Low Price Pharma Stocks To Invest In

11 Best Low Price Pharma Stocks To Invest In
Insider Monkey 6 days ago
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Zacks 8 days ago
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Zacks 9 days ago
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Business Wire 10 days ago
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Business Wire 11 days ago
Israeli economy has proven to thrive despite crisis: Expert

Israeli economy has proven to thrive despite crisis: Expert
Yahoo Finance Video 11 days ago
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Business Wire 16 days ago
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
Business Wire 17 days ago
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
Business Wire 20 days ago
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Business Wire 23 days ago
3 No-Brainer Stocks to Buy With $600 Right Now

3 No-Brainer Stocks to Buy With $600 Right Now
Motley Fool 24 days ago
View More

Related Tickers

VTRS Viatris Inc.
11.57
+0.87%
 
ELAN Elanco Animal Health Incorporated
13.26
+1.69%
 
BHC Bausch Health Companies Inc.
8.71
+1.04%
 
TLRY Tilray Brands, Inc.
1.7800
+1.71%
 
ACB Aurora Cannabis Inc.
6.70
-0.15%
 
CGC Canopy Growth Corporation
8.91
+2.41%
 
PRGO Perrigo Company plc
31.94
+2.14%
 
DVAX Dynavax Technologies Corporation
11.21
+0.36%
 
ESPR Esperion Therapeutics, Inc.
1.9000
-4.52%
 
ALVO Alvotech
14.15
+3.66%